Dossier assessment
Ibrutinib (CLL) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Ibrutinib (CLL) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Ibrutinib (CLL) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
| Adults with previously untreated chronic lymphocytic leukaemia (CLL) |
| Patients in good general health for whom therapy with fludarabine + cyclophosphamide + rituximab is an option: indication of major added benefit. Other research questions: added benefit not proven. |
Press releases
Ibrutinib with rituximab in previously untreated CLL: indication of added benefit over FCR
Project details
- Project no.
- A20-88
- Commission
- Commission awarded on 01.10.2020 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Ibrutinib (new therapeutic indication, Waldenström macroglobulinaemia) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Ibrutinib (new therapeutic indication, chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Ibrutinib (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Ibrutinib (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Ibrutinib - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Ibrutinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Ibrutinib (chronic lymphocytic leukaemia, first line) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed